Generic placeholder image

Current Alzheimer Research

Author(s): Soo-Hyun Cho, Hak Y. Rhee, Janghoon Oh, Jin S. Lee, Soonchan Park, Won C. Shin, Jong-Woo Paik, Chang-Woo Ryu, Key C. Park and Geon-Ho Jahng*

DOI: 10.2174/1567205018666210708145924

DownloadDownload PDF Flyer Cite As
Longitudinal Functional Magnetic Resonance Spectroscopy Study in Subjects with Mild Cognitive Impairment and Alzheimer’s Disease

Page: [335 - 346] Pages: 12

  • * (Excluding Mailing and Handling)

Abstract

Background: Longitudinal changes of brain metabolites during a functional stimulation are unknown in amnestic mild cognitive impairment (aMCI) and Alzheimer’s disease (AD) subjects.

Objective: This study was to evaluate the longitudinal changes of brain metabolites using proton magnetic resonance spectroscopy (1H MRS) in response to treatment during a memory task in the subjects of cognitive normal (CN), aMCI, and AD.

Methods: We acquired functional magnetic resonance spectroscopy (fMRS) data from 28 CN elderly, 16 aMCI and 12 AD subjects during a face-name association task. We measured fMRS metabolite ratios over 24 months in the 8-month apart, determined the temporal changes of the metabolites, and evaluated the differences among the three groups under the three different conditions (base, novel, repeat).

Results: The results of comparisons for the three subject groups and the three-time points showed that tNAA/tCho and tCr/tCho were statistically significant among the three subject groups in any of the three conditions. The dynamic temporal change measurements for the metabolites for each condition showed that Glx/tCho and Glu/tCho levels at the third visit increased significantly compared with in the first visit in the novel condition in the AD group.

Conclusion: We found declines in tNAA/tCho and tCr/tCho in the aMCI and AD subjects with increasing disease severity, being highest in CN and lowest in AD. The Glx/tCho level increased temporally in the AD subjects after they took an acetylcholine esterase inhibitor. Therefore, Glx may be suitable to demonstrate functional recovery after treatment.

Keywords: Longitudinal study, functional magnetic resonance spectroscopy, Alzheimer's disease, mild cognitive impairment, glutamine and glutamate complex (Glx), total N-acetylaspartate (tNAA).

[1]
Graff-Radford J, Kantarci K. Magnetic resonance spectroscopy in Alzheimer’s disease. Neuropsychiatr Dis Treat 2013; 9: 687-96.
[PMID: 23696705]
[2]
Mandal K, Pravat . Magnetic Resonance Spectroscopy (MRS) and its application in Alzheimer’s disease. Concepts Magnetic Resonance Part A 2007; 30A(1): 40-64.
[http://dx.doi.org/10.1002/cmr.a.20072]
[3]
Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: Effects of normal aging. Magn Reson Med 1999; 41(2): 276-84.
[http://dx.doi.org/10.1002/(SICI)1522-2594(199902)41:2<276::AID-MRM10>3.0.CO;2-8] [PMID: 10080274]
[4]
Criteria for the clinical diagnosis of Alzheimer’s disease. Excerpts from the NINCDS-ADRDA work group report. J Am Geriatr Soc 1985; 33(1): 2-3.
[http://dx.doi.org/10.1111/j.1532-5415.1985.tb02850.x] [PMID: 3965552]
[5]
Haga KK, Khor YP, Farrall A, Wardlaw JM. A systematic review of brain metabolite changes, measured with 1H magnetic resonance spectroscopy, in healthy aging. Neurobiol Aging 2009; 30(3): 353-63.
[http://dx.doi.org/10.1016/j.neurobiolaging.2007.07.005] [PMID: 17719145]
[6]
Shulman RG, Hyder F, Rothman DL. Biophysical basis of brain activity: Implications for neuroimaging. Q Rev Biophys 2002; 35(3): 287-325.
[http://dx.doi.org/10.1017/S0033583502003803] [PMID: 12599751]
[7]
Clare L, Wilson BA, Carter G, Roth I, Hodges JR. Relearning face name associations in early Alzheimer’s disease. Neuropsychology 2002; 16(4): 538-47.
[http://dx.doi.org/10.1037/0894-4105.16.4.538] [PMID: 12382992]
[8]
Sperling RA, Laviolette PS, O’Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009; 63(2): 178-88.
[http://dx.doi.org/10.1016/j.neuron.2009.07.003] [PMID: 19640477]
[9]
Jahng GH, Oh J, Lee DW, et al. Glutamine and glutamate complex, as measured by functional magnetic resonance spectroscopy, alters during face-name association task in patients with mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis 2016; 52(1): 145-59.
[http://dx.doi.org/10.3233/JAD-150877] [PMID: 27060946]
[10]
Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58(12): 1985-92.
[http://dx.doi.org/10.1001/archneur.58.12.1985] [PMID: 11735772]
[11]
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999; 56(3): 303-8.
[http://dx.doi.org/10.1001/archneur.56.3.303] [PMID: 10190820]
[12]
Tierney MC, Fisher RH, Lewis AJ, et al. The NINCDS-ADRDA work group criteria for the clinical diagnosis of probable Alzheimer’s disease: A clinicopathologic study of 57 cases. Neurology 1988; 38(3): 359-64.
[http://dx.doi.org/10.1212/WNL.38.3.359] [PMID: 3347338]
[13]
Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCmodel. NMR Biomed 2001; 14(4): 260-4.
[http://dx.doi.org/10.1002/nbm.698] [PMID: 11410943]
[14]
Yüksel C, Öngür D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry 2010; 68(9): 785-94.
[http://dx.doi.org/10.1016/j.biopsych.2010.06.016] [PMID: 20728076]
[15]
Huang Z, Davis HH IV, Yue Q, et al. Increase in glutamate/glutamine concentration in the medial prefrontal cortex during mental imagery: A combined functional mrs and fMRI study. Hum Brain Mapp 2015; 36(8): 3204-12.
[http://dx.doi.org/10.1002/hbm.22841] [PMID: 26059006]
[16]
Cleve M, Gussew A, Reichenbach JR. In vivo detection of acute pain-induced changes of GABA+ and Glx in the human brain by using functional 1H MEGA-PRESS MR spectroscopy. Neuroimage 2015; 105: 67-75.
[http://dx.doi.org/10.1016/j.neuroimage.2014.10.042] [PMID: 25462698]
[17]
Penner J, Rupsingh R, Smith M, Wells JL, Borrie MJ, Bartha R. Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(1): 104-10.
[http://dx.doi.org/10.1016/j.pnpbp.2009.10.007] [PMID: 19833161]
[18]
Maddock RJ, Buonocore MH. MR spectroscopic studies of the brain in psychiatric disorders. Curr Top Behav Neurosci 2012; 11: 199-251.
[http://dx.doi.org/10.1007/7854_2011_197] [PMID: 22294088]
[19]
Krishnan KR, Charles HC, Doraiswamy PM, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease. Am J Psychiatry 2003; 160(11): 2003-11.
[http://dx.doi.org/10.1176/appi.ajp.160.11.2003] [PMID: 14594748]
[20]
Jessen F, Traeber F, Freymann K, Maier W, Schild HH, Block W. Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 2006; 67(3): 528-30.
[http://dx.doi.org/10.1212/01.wnl.0000228218.68451.31] [PMID: 16894124]